---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-029717"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2025-09-23T23:59:59+00:00"
generated_at: "2026-05-17T05:51:23.329416+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k

## Summary
- Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.
- Q4 net loss $178k ($0.01 loss per share) vs net income $268k ($0.01 EPS) prior year; tax expense $773k.
- FY2025 revenue $54.4M (+8.0%); net income $808k ($0.03 diluted EPS) vs $112k ($0.00 EPS) prior year.
- FY operating income $2.0M vs $251k; selling and administrative expenses flat.
- Weighted average diluted shares for FY 31.2M vs 30.9M.

## SEC filing metadata
- accession: 0001437749-25-029717
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2025-09-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774925029717/0001437749-25-029717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774925029717/inbp20250922_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-029717
- JSON: https://secwatch.observer/filing/0001437749-25-029717.json
- Plain text: https://secwatch.observer/filing/0001437749-25-029717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.